Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01759303 · ClinicalTrials.gov registry record · Phase 2
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
A Phase 2 study, sponsored by Emerald Clinical.
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT01759303: Clinical Trial Phase 2 study, sponsored by Emerald Clinical.
NCT01759303 is a Phase 2 study that was terminated before completion, run by Emerald Clinical. The registered enrollment target is 12 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01759303, a Phase 2 study, was terminated before completion, sponsored by Emerald Clinical.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with demonstrated increase in tumor doubling time, of eligible subjects treated with pazopanib according to RECIST version 1.1 guidelines.
Primary Outcome
The primary objective of the study is to evaluate the 4-month PFS (with demonstrated increase in tumor doubling time) of eligible subjects treated with pazopanib according to RECIST version 1.1 guidelines. Tumor growth rate will be calculated by measuring growth at the specified intervals for the single, longest dimension of the tumor(s) (RECIST) and by calculating the area of the tumor(s), which will be the product of the longest dimension of the tumor(s) multiplied by its longest, perpendicul
Interventions
- DRUG pazopanib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2013-04 |
| Est. Completion | 2017-05 |
| Phase | Phase 2 |
Why NCT01759303 stopped before completion
NCT01759303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which pazopanib is the first listed.
NCT01759303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01759303 about?
NCT01759303 is a clinical study titled "Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung". The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with demonstrated increase in tumor doubling time, of eligible subjects treated with pazopanib according to RECIST version 1.1 guidelines.
What is the current status of trial NCT01759303?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2013-04. Estimated completion is 2017-05.
What interventions are being tested in trial NCT01759303?
The interventions under investigation include: pazopanib (DRUG).
Who is sponsoring clinical trial NCT01759303?
This trial is sponsored by Emerald Clinical, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01759303's enrollment target sits among peer trials
12 1948th of 2000 higher than 34 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia